SOURCE: VIVALIS

August 22, 2007 04:09 ET

VIVALIS STRENGTHENS ITS INTELLECTUAL PROPERTY PORTFOLIO

NANTES, FRANCE--(Marketwire - August 22, 2007) - VIVALIS STRENGTHENS ITS INTELLECTUAL PROPERTY PORTFOLIO WITH A WORLDWIDE EXCLUSIVE LICENSE AGREEMENT WITH NORTH CAROLINA STATE UNIVERSITY

Nantes (France) and Raleigh (NC, USA) - August 21st, 2007

Vivalis (NYSE-Euronext : VLS) has recently completed official arrangements to license platform technology from North Carolina State University (NCSU) describing a method of producing undifferentiated avian cell cultures using avian primordial germ (PGC) cells. This new license related to culture processes & culture media for avian stem cells supplements the 2 licences already signed with NORTH CAROLINA STATE UNIVERSITY in 2002.

Thanks to this new agreement, VIVALIS confirms its worldwide leadership in avian stem cell lines and strengthens the intellectual protection of its breakthrough cell technology.

The licensed technology is covered by US patent N degrees6,333,192 and Europe patent N degreesEP1,200,556. Additional patent applications protecting this discovery are pending.

The license grants VIVALIS exclusive rights to apply the methodology worldwide. The financial terms of the license remain confidential.

Franck GRIMAUD, VIVALIS CEO declared : "We are very pleased to have signed this exclusive license with North Carolina State University. This agreement will strongly reinforce our intellectual property position on the industrial applications of ES cells. Vivalis now has built a world-wide unique and exhaustive avian ES cell IP portfolio, which is positioning us as the sole IP and technology provider in this field ".

Vivalis partnered with NC State's Office of Technology Transfer (OTT) to coordinate the official licensing arrangements with the University. OTT is responsible for collaboratively fulfilling the university's mandate to benefit the greater public good through the transfer of academic research and discovery to the marketplace.

*******************

Next calendar:

August 30th, after Euronext closing: First half 2007 results

About VIVALIS (www.vivalis.com)

Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company specialised in vaccines and in viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants commercial licences to its proprietary EBx® embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.

- Recombinant therapeutic protein and monoclonal antibody expression systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary EBx® embryonic stem cell lines to manufacture recombinant therapeutic proteins.

- The build-up of a proprietary portfolio of vaccines and anti- viral molecules.

Based in Nantes (France), Vivalis was created in 1999 by Group GRIMAUD (1350 employees), the n degrees2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

About NORTH CAROLINA STATE UNIVERSITY

Located in Raleigh, North Carolina, and founded in 1887 as a land- grant university, North Carolina State University today is one of the United States' top public research universities. It holds more than 570 U.S. patents and invests more than $444 million annually in research, training and extension.

B Compartment of Eurolist Paris - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

Investors Contact:

VIVALIS NewCap

Franck Grimaud, C.E.O. Financial communication Agency

Email: investors@vivalis.com Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr

This information is provided by CompanynewsGroup

Contact Information